Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 16;16(4):e0250339.
doi: 10.1371/journal.pone.0250339. eCollection 2021.

A dose-dependent beneficial effect of methotrexate on the risk of interstitial lung disease in rheumatoid arthritis patients

Joanna Kur-Zalewska  1   2 , Bartłomiej Kisiel  1   2 , Marta Kania-Pudło  3 , Małgorzata Tłustochowicz  1 , Andrzej Chciałowski  4 , Witold Tłustochowicz  1
Affiliations

A dose-dependent beneficial effect of methotrexate on the risk of interstitial lung disease in rheumatoid arthritis patients

Joanna Kur-Zalewska et al. PLoS One. .

Abstract

Objectives: The aim of the study was to assess the influence of different factors, including treatment, on the risk of ILD in the course of RA.

Methods: A total of 109 RA patients were included in the analysis. High-resolution computed tomography (HRCT) of chest was obtained in each patient. Patients were classified as having ILD (ILD group) or not (N-ILD group). The ILD was graded using the semi-quantitative Warrick scale of fibrosis. Warrick extent score (WES) and Warrick severity score (WSS) were calculated separately for each patient, then combined to obtain a global score (WGS).

Results: In univariate analysis the presence of ILD was associated positively with age (P = 5x10-6) and negatively with MTX treatment (P = 0.0013), mean MTX dose per year of treatment (P = 0.003) and number of DMARDs used (P = 0.046). On multivariate analysis only age and treatment with MTX were independently associated with the presence of ILD. WGS was significantly lower in patients treated with MTX in a dose of ≥15 mg/week (MTX≥15 group) as compared to patients treated with lower doses of MTX (0<MTX<15 group) or not treated with MTX (N-MTX group) (P = 0.04 and P = 0.037, respectively). The ILD prevalence was higher in N-MTX group than in 0<MTX<15 group (P = 0.0036) and MTX≥15 group (0.0007). The difference in ILD prevalence between MTX≥15 and 0<MTX<15 groups was not significant, but the latter group had higher WES (P = 0.044) and trended to have higher WSS and WGS.

Consclusions: We found a beneficial effect of MTX on RA-ILD. Importantly, this effect seems to be dose dependent.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Habib HM, Eisa AA, Arafat WR, Marie MA. Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol. 2011;30: 217–221. 10.1007/s10067-010-1492-5 - DOI - PubMed
    1. Rockall AG, Rickards D, Shaw PJ. Imaging of the pulmonary manifestations of systemic disease. Postgrad Med J. 2001;77: 621–638. 10.1136/pmj.77.912.621 - DOI - PMC - PubMed
    1. Sidhu HS, Bhatnagar G, Bhogal P, Riordan R. Imaging features of the pleuropulmonary manifestations of rheumatoid arthritis: pearls and pitfalls. J Clin Imaging Sci. 2011;1: 32. Available from: http://www.clinicalimagingscience.org/text.asp?2011/1/1/32/82244 10.4103/2156-7514.82244 - DOI - PMC - PubMed
    1. Ishida T, Kotani T, Takeuchi T, Makino S. Pulmonary toxicity after initiation of azathioprine for treatment of interstitial pneumonia in a patient with rheumatoid arthritis. J Rheumatol. 2012;39: 1104–1105. 10.3899/jrheum.111415 - DOI - PubMed
    1. Tsuchiya Y, Takayanagi N, Sugiura H, Miyahara Y, Tokunaga D, Kawabata Y, et al.. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J. 2011;37: 1411–1417. 10.1183/09031936.00019210 - DOI - PubMed